Response to mepolizumab treatment in patients with severe eosinophilic asthma and atopic phenotypes
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Journal of asthma and allergy. - 14 (2021) , 675-683, ISSN: 1178-6965
- Event
-
Veröffentlichung
- (where)
-
Freiburg
- (who)
-
Universität
- (when)
-
2021
- Creator
-
Prazma, Charlene M
Idzko, Marco
Douglass, Jo Anne
Bourdin, Arnaud
Mallett, Stephen
Albers, Frank C
Yancey, Steven W
- DOI
-
10.2147/JAA.S298559
- URN
-
urn:nbn:de:bsz:25-freidok-2193610
- Rights
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:50 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Prazma, Charlene M
- Idzko, Marco
- Douglass, Jo Anne
- Bourdin, Arnaud
- Mallett, Stephen
- Albers, Frank C
- Yancey, Steven W
- Universität
Time of origin
- 2021
Other Objects (12)
Ligelizumab treatment for severe asthma: learnings from the clinical development programme
Hospitalization, asthma phenotypes, and readmission rates in pre-school asthma
FADS gene variants, diet and atopic phenotypes and lipids in children
FADS gene variants, diet and atopic phenotypes and lipids in children
Successful treatment of severe atopic dermatitis with calcitriol and paricalcitol in an 8-year-old girl
Atopic dermatitis : from pathognesis to treatment
Alpine altitude climate treatment for severe and uncontrolled asthma: an EAACI position paper
Update "Systemic treatment of atopic dermatitis" of the S2k‐guideline on atopic dermatitis
Tiotropium as an add-on treatment option for severe uncontrolled asthma in preschool patients
S3 guideline Atopic dermatitis: part 2 ‐ systemic treatment
Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go?
Patients with moderate-to-severe atopic dermatitis maintain stable response with no or minimal fluctuations with 1 year of lebrikizumab treatment
Ligelizumab treatment for severe asthma: learnings from the clinical development programme
Hospitalization, asthma phenotypes, and readmission rates in pre-school asthma
FADS gene variants, diet and atopic phenotypes and lipids in children
FADS gene variants, diet and atopic phenotypes and lipids in children
Successful treatment of severe atopic dermatitis with calcitriol and paricalcitol in an 8-year-old girl
Atopic dermatitis : from pathognesis to treatment
Alpine altitude climate treatment for severe and uncontrolled asthma: an EAACI position paper
Update "Systemic treatment of atopic dermatitis" of the S2k‐guideline on atopic dermatitis
Tiotropium as an add-on treatment option for severe uncontrolled asthma in preschool patients
S3 guideline Atopic dermatitis: part 2 ‐ systemic treatment
Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go?
Patients with moderate-to-severe atopic dermatitis maintain stable response with no or minimal fluctuations with 1 year of lebrikizumab treatment
Ligelizumab treatment for severe asthma: learnings from the clinical development programme
Hospitalization, asthma phenotypes, and readmission rates in pre-school asthma
FADS gene variants, diet and atopic phenotypes and lipids in children
FADS gene variants, diet and atopic phenotypes and lipids in children
Successful treatment of severe atopic dermatitis with calcitriol and paricalcitol in an 8-year-old girl
Atopic dermatitis : from pathognesis to treatment
Alpine altitude climate treatment for severe and uncontrolled asthma: an EAACI position paper
Update "Systemic treatment of atopic dermatitis" of the S2k‐guideline on atopic dermatitis
Tiotropium as an add-on treatment option for severe uncontrolled asthma in preschool patients
S3 guideline Atopic dermatitis: part 2 ‐ systemic treatment
Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go?